ACTRN12613000604707
Not yet recruiting
未知
Investigation to measure and evaluate the effects of a geothermal water on Psoriasis
QE Health0 sites33 target enrollmentMay 28, 2013
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- QE Health
- Enrollment
- 33
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Documented proof of diagnosis of Psoriasis, and have active psoriatic skin condition
- •Able to access bath used for treatment, able to attend treatments as scheduled and understands the study procedures and risks involved, and voluntarily agrees to participate by giving written informed consent
Exclusion Criteria
- •Currently participating, or has participated, in a research study when treatment occurred within the last 3 months
- •Has skin condition other than psoriasis
- •Has broken skin (open cracks in psoriatic lesions are not an exclusion).
- •Has a significant medical condition or history which may interfere with full participation in the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
How SGLT2-I and and Angiotensin receptor blockers together affect Diabetic kidney diseaseHealth Condition 1: E112- Type 2 diabetes mellitus with kidney complicationsCTRI/2022/05/042657Thakurpukur Medical Society
Completed
Not Applicable
Examination of the effects induced by research-food intakes continuously on immune parameters.Healthy male/female adultsJPRN-UMIN000046959CPCC Company Limited140
Completed
Phase 2
Counselling by nurse will improve medical adherence, patient satisfaction, sinonasal quality and visual quality of life in post operative patients of pituitary tumors.Health Condition 1: E229- Hyperfunction of pituitary gland,unspecifiedCTRI/2019/06/019505Postgraduate Institute of Medical Education and Research Chandigarh60
Active, not recruiting
Not Applicable
A Mechanism of Action study to evaluate the effects of IL-6receptor blockade with tocilizumab (TCZ) on lipids, arterialstiffness, and markers of atherogenic risk in patients withmoderate to severe active rheumatoid arthritis (RA).EUCTR2007-001114-17-GBF. Hoffmann-La Roche Limited120
Completed
Phase 2
Evaluation of the occurrence, effect and side effects oFcyclophosfamid and rituximab in the tratment of children with NEPHROTIC SYNDROM resistance to STEROID that referred to Hazrate Massumeh hospital .IRCT20170527034146N2Ghoum University of Medical Sciences102